Mikhail Blagosklonny - История изменений

Rodion: /* References */

2024-10-22T08:18:04Z

References

← Предыдущая версия		Версия от 11:18, 22 октября 2024
Строка 23:		Строка 23:
	Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain. He died in October 2024 at the age of 63.		Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain. He died in October 2024 at the age of 63.

	~~==References==~~
	~~{{reflist\|30em}}~~

	* {{Wikipedia\|Mikhail Blagosklonny}}		* {{Wikipedia\|Mikhail Blagosklonny}}

Rodion: /* Health */

2024-10-22T08:17:54Z

Health

← Предыдущая версия		Версия от 11:17, 22 октября 2024
Строка 21:		Строка 21:
	==Health==		==Health==

	Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.~~<ref>{{cite web \|url=https://www.mikhailblagosklonny.com/blog/my-battle-with-cancer/\|title = My battle with cancer\|date = 26 October 2023}}</ref>~~ He died in October 2024 at the age of 63.~~<ref>{{cite web\|url=https://www.rapamycin.news/t/passing-of-dr-misha-blagoskonny/16658\|title=Passing of Dr. Misha Blagoskonny\|work=Rapamycin News\|access-date=2024-10-09}}</ref>~~		Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain. He died in October 2024 at the age of 63.

	==References==		==References==

Rodion: /* Editorial activities */

2024-10-22T08:17:38Z

Editorial activities

← Предыдущая версия		Версия от 11:17, 22 октября 2024
Строка 15:		Строка 15:
	== Editorial activities==		== Editorial activities==

	Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy~~[9]~~ and a member of the editorial board of Cell Death & Differentiation.		Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy and a member of the editorial board of Cell Death & Differentiation.

	The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015. Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.		The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015. Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.

Rodion: /* Editorial activities */

2024-10-22T08:17:24Z

Editorial activities

← Предыдущая версия		Версия от 11:17, 22 октября 2024
Строка 14:		Строка 14:

	== Editorial activities==		== Editorial activities==
	Blagosklonny is [[editor-in-chief]] of [[Aging (journal)\|''Aging'']],<ref>{{Cite web \|url=http://www.impactaging.com/editors.html \|archive-url=https://web.archive.org/web/20090125145825/http://impactaging.com/editors.html \|url-status=dead \|archive-date=2009-01-25 \|work=Aging \|title=Editorial Board \|accessdate=2016-11-20}}</ref> [[Cell Cycle (journal)\|''Cell Cycle'']],<ref>{{Cite web \|url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kccy20 \|work=Cell Cycle \|title=Editorial Board \|accessdate=2016-11-20 \|publisher=[[Taylor & Francis]]}}</ref> and ''[[Oncotarget]]''.<ref>{{Cite web \|url=http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=pages&op=view&path%5B%5D=board \|work=Oncotarget \|title=Editorial Board \|accessdate=2016-11-20}}</ref> In addition, he is associate editor of ''[[Cancer Biology & Therapy]]''<ref>{{cite web \|url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kcbt20 \|work=Cancer Biology & Therapy \|title=Editorial board \|publisher=Taylor & Francis\|accessdate=2016-11-20}}</ref> and a member of the [[editorial board]] of ''[[Cell Death & Differentiation]]''.<ref>{{cite web \|url=http://www.nature.com/cdd/about.html \|work=[[Cell Death & Differentiation]] \|title=About the journal \|accessdate=2016-11-20}}</ref>

	The [[peer review]] process employed by ''Oncotarget'' has been criticized by [[Jeffrey Beall]],<ref name=Beall>{{cite web\|last1=Beall \|first1=Jeffrey \|authorlink1=Jeffrey Beall \|title=Oncotarget's Peer Review is Highly Questionable \|url=https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ \|website=Scholarly Open Access \|accessdate=2016-11-20 \|date=19 April 2016 \|url-status=dead \|archiveurl=https://web.archive.org/web/20160420235706/https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ \|archivedate=20 April 2016 }}</ref> a university librarian and expert on [[predatory open access publishing]], who also included ''Oncotarget'' and ''Aging'' on his list of "potential, possible, or probable predatory scholarly open-access journals"<ref>{{cite web\|last1=Beall \|first1=Jeffrey \|authorlink1=Jeffrey Beall \|title=LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals \|url=https://scholarlyoa.com/individual-journals/ \|website=Scholarly Open Access \|accessdate=19 April 2016 \|date=2016-11-20 \|url-status=dead \|archiveurl=https://web.archive.org/web/20161202192038/https://scholarlyoa.com/individual-journals/ \|archivedate=2 December 2016 }}</ref> in July 2015.~~<ref name=Beall/>~~ Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his ~~[[Author-level metrics\|~~personal citation impact~~]].<ref>{{cite web\|url=https://scholarlyoa~~.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ \|title=Mikhail Blagosklonny's Journal Aging: A Review \|website=Scholarly Open Access \|date=6 December 2016 \|accessdate=17 January 2017 \|archiveurl=https://web.archive.org/web/20161224004259/https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ \|archivedate=24 December 2016 \|url-status=dead }}</ref>		Blagosklonny is editor-in-chief of Aging, Cell Cycle, and Oncotarget. In addition, he is associate editor of Cancer Biology & Therapy[9] and a member of the editorial board of Cell Death & Differentiation.

			The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015. Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.

	==Health==		==Health==

Rodion: /* Rapamycin and aging */

2024-10-22T08:14:55Z

Rapamycin and aging

← Предыдущая версия		Версия от 11:14, 22 октября 2024
Строка 10:		Строка 10:

	==Rapamycin and aging==		==Rapamycin and aging==
	Blagosklonny has formulated a hypothesis about the possible role of [[TOR signaling]] in aging and cancer and proposed using [[rapamycin]], a popular cancer drug as a possible treatment for life extension.~~<ref>{{cite journal \|first=David\|last=Stipp\|title=A New Path to Longevity \|journal=~~[~~[Scientific American]~~] ~~\|date=2011 \|volume=306\|issue=1\|doi=10.1038/scientificamerican0112-32 \|pages=32–39\|pmid=22279832\|bibcode=2011SciAm.306f..32S}}</ref>~~ He advocates for rapamycin use in longevity research.<ref>{{cite news \|url=https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-\|title = Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015\|newspaper = Bloomberg.com\|date = 12 February 2015\|accessdate = November 20, 2016}}</ref>
			Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[4] He advocates for rapamycin use in longevity research.

	== Editorial activities==		== Editorial activities==

Rodion в 08:13, 22 октября 2024

2024-10-22T08:13:18Z

@@ Строка 1: / Строка 1: @@
 {{Languages|Михаил Благосклонный}}
-{{Infobox scientist
+==Career==
-==Career==
+Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Comprehensive Cancer Center.
-Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging ([[biogerontology]]) and anti-aging drugs.<ref>{{Cite journal|date=May 2009|title=Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute|journal=Cancer Biology & Therapy|volume=8|issue=9|pages=753–752|doi=10.4161/cbt.8.9.8899|doi-access=free}}</ref> Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.<ref name=":0" />
+Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs. Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.
 ==Rapamycin and aging==

Rodion в 08:12, 22 октября 2024

2024-10-22T08:12:37Z

← Предыдущая версия		Версия от 11:12, 22 октября 2024
Строка 1:		Строка 1:
	{{Languages\|Михаил Благосклонный}}		{{Languages\|Михаил Благосклонный}}

			{{Infobox scientist
			\| name = Mikhail Blagosklonny
			\| image =
			\| image_size =
			\| caption =
			\| birth_date =
			\| birth_place =
			\| field = [[Anti-aging medicine]], [[oncology]]
			\| work_institutions = {{plainlist\|1=
			*[[New York Medical College]]
			*[[Roswell Park Comprehensive Cancer Center]]
			}}
			\| alma_mater = [[First Pavlov State Medical University of St. Peterburg]]
			\| education =
			\| website =
			}}
			'''Mikhail Blagosklonny''' was a scientist who studied [[cancer]] and [[aging]]. He died in October 2024. He was an adjunct faculty member at [[Roswell Park Comprehensive Cancer Center]] in [[Buffalo, New York]].<ref name=":0">{{Cite web\|title=About Mikhail Blagosklonny\|url=https://www.roswellpark.org/mikhail-blagosklonny\|access-date=May 14, 2021\|website=[[Roswell Park Comprehensive Cancer Center]]}}</ref>

			==Career==
			Blagosklonny earned both his [[M.D.]] in internal medicine and his [[PhD]] in experimental medicine and cardiology from the [[First Pavlov State Medical University of St. Petersburg]].{{citation needed\|date=November 2017}} He was appointed associate professor of medicine at [[New York Medical College]], Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute ([[Albany, New York]]). Blagosklonny held this position until 2009, when he was appointed professor of oncology at [[Roswell Park Comprehensive Cancer Center]].<ref name="Roswell Park Cancer Institute">{{citation
			\| date = May 2009
			\| doi = 10.4161/cbt.8.9.8899
			\| issue = 9
			\| journal = Cancer Biology & Therapy
			\| pages = 753–752
			\| title = Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute
			\| volume = 8\| doi-access = free
			}}</ref>

			Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging ([[biogerontology]]) and anti-aging drugs.<ref>{{Cite journal\|date=May 2009\|title=Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute\|journal=Cancer Biology & Therapy\|volume=8\|issue=9\|pages=753–752\|doi=10.4161/cbt.8.9.8899\|doi-access=free}}</ref> Roswell Park Comprehensive Cancer Center lists Blagosklonny as holding "Adjunct Faculty" and "Cell Stress Biology" positions with them.<ref name=":0" />

			==Rapamycin and aging==
			Blagosklonny has formulated a hypothesis about the possible role of [[TOR signaling]] in aging and cancer and proposed using [[rapamycin]], a popular cancer drug as a possible treatment for life extension.<ref>{{cite journal \|first=David\|last=Stipp\|title=A New Path to Longevity \|journal=[[Scientific American]] \|date=2011 \|volume=306\|issue=1\|doi=10.1038/scientificamerican0112-32 \|pages=32–39\|pmid=22279832\|bibcode=2011SciAm.306f..32S}}</ref> He advocates for rapamycin use in longevity research.<ref>{{cite news \|url=https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-\|title = Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015\|newspaper = Bloomberg.com\|date = 12 February 2015\|accessdate = November 20, 2016}}</ref>

			== Editorial activities==
			Blagosklonny is [[editor-in-chief]] of [[Aging (journal)\|''Aging'']],<ref>{{Cite web \|url=http://www.impactaging.com/editors.html \|archive-url=https://web.archive.org/web/20090125145825/http://impactaging.com/editors.html \|url-status=dead \|archive-date=2009-01-25 \|work=Aging \|title=Editorial Board \|accessdate=2016-11-20}}</ref> [[Cell Cycle (journal)\|''Cell Cycle'']],<ref>{{Cite web \|url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kccy20 \|work=Cell Cycle \|title=Editorial Board \|accessdate=2016-11-20 \|publisher=[[Taylor & Francis]]}}</ref> and ''[[Oncotarget]]''.<ref>{{Cite web \|url=http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=pages&op=view&path%5B%5D=board \|work=Oncotarget \|title=Editorial Board \|accessdate=2016-11-20}}</ref> In addition, he is associate editor of ''[[Cancer Biology & Therapy]]''<ref>{{cite web \|url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kcbt20 \|work=Cancer Biology & Therapy \|title=Editorial board \|publisher=Taylor & Francis\|accessdate=2016-11-20}}</ref> and a member of the [[editorial board]] of ''[[Cell Death & Differentiation]]''.<ref>{{cite web \|url=http://www.nature.com/cdd/about.html \|work=[[Cell Death & Differentiation]] \|title=About the journal \|accessdate=2016-11-20}}</ref>

			The [[peer review]] process employed by ''Oncotarget'' has been criticized by [[Jeffrey Beall]],<ref name=Beall>{{cite web\|last1=Beall \|first1=Jeffrey \|authorlink1=Jeffrey Beall \|title=Oncotarget's Peer Review is Highly Questionable \|url=https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ \|website=Scholarly Open Access \|accessdate=2016-11-20 \|date=19 April 2016 \|url-status=dead \|archiveurl=https://web.archive.org/web/20160420235706/https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ \|archivedate=20 April 2016 }}</ref> a university librarian and expert on [[predatory open access publishing]], who also included ''Oncotarget'' and ''Aging'' on his list of "potential, possible, or probable predatory scholarly open-access journals"<ref>{{cite web\|last1=Beall \|first1=Jeffrey \|authorlink1=Jeffrey Beall \|title=LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals \|url=https://scholarlyoa.com/individual-journals/ \|website=Scholarly Open Access \|accessdate=19 April 2016 \|date=2016-11-20 \|url-status=dead \|archiveurl=https://web.archive.org/web/20161202192038/https://scholarlyoa.com/individual-journals/ \|archivedate=2 December 2016 }}</ref> in July 2015.<ref name=Beall/> Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his [[Author-level metrics\|personal citation impact]].<ref>{{cite web\|url=https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ \|title=Mikhail Blagosklonny's Journal Aging: A Review \|website=Scholarly Open Access \|date=6 December 2016 \|accessdate=17 January 2017 \|archiveurl=https://web.archive.org/web/20161224004259/https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ \|archivedate=24 December 2016 \|url-status=dead }}</ref>

			==Health==

			Blagosklonny announced that in January 2023 he was diagnosed with numerous metastases of lung cancer in his brain.<ref>{{cite web \|url=https://www.mikhailblagosklonny.com/blog/my-battle-with-cancer/\|title = My battle with cancer\|date = 26 October 2023}}</ref> He died in October 2024 at the age of 63.<ref>{{cite web\|url=https://www.rapamycin.news/t/passing-of-dr-misha-blagoskonny/16658\|title=Passing of Dr. Misha Blagoskonny\|work=Rapamycin News\|access-date=2024-10-09}}</ref>

			==References==
			{{reflist\|30em}}

			* {{Wikipedia\|Mikhail Blagosklonny}}

Rodion: Новая страница: «{{Languages|Михаил Благосклонный}}»

2024-10-22T08:11:32Z

Новая страница: «{{Languages|Михаил Благосклонный}}»

Новая страница